Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Arvinas (Nasdaq: ARVN) granted an inducement award of 45,696 restricted stock units (RSUs) to one newly hired employee, effective August 31, 2026, under Nasdaq Listing Rule 5635(c)(4). The award was made outside the company’s stock incentive plan and will vest in full on the first anniversary of the grant date, subject to the employee’s continued service with Arvinas.

Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapies via its PROTAC platform and is advancing multiple investigational drugs in oncology and neurological indications.

Market Context

ARVN’s historical record included a 0.52% 24-hour move after June 4 collaboration news, placing this...

Analysis

ARVN’s historical record included a 0.52% 24-hour move after June 4 collaboration news, placing this compensation disclosure beside varied outcomes; recent insider data showed Net Selling, a risk to monitor.

Key Figures

RSU award: 45,696 restricted stock units Vesting period: one year Nasdaq rule: 5635(c)(4)

3 metrics

RSU award 45,696 restricted stock units One newly hired employee

Vesting period one year Full vesting on the anniversary of the August 31, 2026 grant date

Nasdaq rule 5635(c)(4) Grant made outside Arvinas’ stock incentive plan

Historical Context

5 past events · Latest: Aug 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 04	Earnings report	Positive	+11.7%	FDA approval, licensing activity, higher revenue, and expanded cash runway
Jul 28	Earnings scheduling	Neutral	-0.2%	Scheduled second-quarter results webcast and corporate update
Jun 04	Research collaboration	Positive	+0.5%	Joined LITE and PPMI programs supporting ARV-102 development
May 29	Conference participation	Neutral	-4.5%	Announced participation in Jefferies Global Healthcare Conference
May 18	Community initiative	Neutral	-3.3%	Held fourth company-wide Impact Day supporting community organizations

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ARVN aligned with positive earnings and collaboration news, while routine conference and corporate announcements were followed by negative reactions.

Key Terms

rsu, nasdaq listing rule 5635(c)(4), protac, heterobifunctional protein degrader

4 terms

rsu financial

"granted 45,696 restricted stock units (“RSU”) to one newly hired employee"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

protac technical

"Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform"

A PROTAC (proteolysis targeting chimera) is a small engineered molecule that tags a specific protein inside cells and brings it to the cell’s disposal machinery so the protein is destroyed rather than just blocked. Think of it as a targeted cleanup crew that removes a problematic part instead of temporarily turning it off. Investors care because PROTACs can tackle disease targets that traditional drugs cannot, creating potential for breakthrough therapies, larger markets, and binary clinical readouts that can sharply affect company value.

heterobifunctional protein degrader technical

"a type of heterobifunctional protein degrader"

A heterobifunctional protein degrader is a designed molecule with two linked ends: one binds a specific target protein and the other recruits the cell’s protein-removal machinery, forcing the cell to tag and destroy the target. Think of it as a molecular bridge that brings a marked item to the cell’s trash system. It matters to investors because it represents a therapeutic approach that can remove disease-related proteins and can expand drug pipelines and valuation prospects for biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

The RSU Award will vest in full on the one-year anniversary of the date of grant. The vesting of the RSU Award is subject to the employee's continued service as an employee of, or other service provider to, Arvinas through the applicable vesting date.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.

Arvinas is currently progressing multiple investigational drugs through or into clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

What inducement equity award did Arvinas (ARVN) grant on August 31, 2026?

Arvinas granted 45,696 restricted stock units as an inducement award to one newly hired employee. According to Arvinas, the RSU award was effective August 31, 2026, and is intended to comply with Nasdaq Listing Rule 5635(c)(4) as a non-plan equity grant.

How do the Arvinas (ARVN) inducement RSUs vest for the new employee?

The inducement RSUs will vest 100% on the one-year anniversary of the August 31, 2026 grant date. According to Arvinas, vesting is conditioned on the recipient’s continued service as an employee or other service provider through the applicable vesting date.

Was the September 2026 Arvinas (ARVN) inducement grant made under its stock incentive plan?

No, the inducement RSU award was not granted under Arvinas’ stock incentive plan. According to Arvinas, the 45,696 RSUs were issued as a standalone inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4) for a newly hired employee.

Why does Arvinas (ARVN) use Nasdaq Listing Rule 5635(c)(4) for this RSU grant?

Arvinas used Nasdaq Listing Rule 5635(c)(4) to issue an equity inducement award to a new hire outside its stock plan. According to Arvinas, this structure supports recruitment while complying with Nasdaq requirements for employment-related equity compensation.

What therapeutic areas is Arvinas (ARVN) focusing on with its PROTAC platform?

Arvinas focuses on debilitating and life-threatening diseases, including cancers and neurological disorders, using its PROTAC protein degrader platform. According to Arvinas, current programs include ARV-393 for non-Hodgkin lymphoma, ARV-102 for neurodegenerative disorders, and additional candidates for solid tumors and rare diseases.

Which FDA-approved PROTAC therapy is associated with Arvinas (ARVN)?

Arvinas co-developed the first FDA-approved PROTAC therapy with Pfizer and then outlicensed it to Rigel Pharmaceuticals. According to Arvinas, Rigel now holds exclusive global rights for development, manufacturing, and commercialization of this heterobifunctional protein degrader.